ADVERTISEMENT
ADVERTISEMENT

Multiprotein DNA/MVA vaccine for AIDS

DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster has controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model.

Tudor Toma(ttoma@mail.dntis.ro)

In a paper published in the online version of Science on 8 March, Amara et al report a two-step AIDS vaccine strategy that can stimulate the immune system to target and eliminate already infected cells (Science 8 March 2001, 10.1126/science.1058915).

The authors used a laboratory-made hybrid of human immunodeficiency virus and simian immunodeficiency virus called SHIV. Amara et al vaccinated rhesus macaques at 0 and 8 weeks, using a DNA prime (DNA/89.6) that expressed SIV Gag, Pol, Vif and Vpx from a single transcript. This was followed by a boost at 24 weeks with a recombinant modified vaccinia Ankara (rMVA) booster that expressed SIV Gag, Pol and HIV1 Env under the control of vaccinia virus early/late promoters. This effectively controlled a challenge with SHIV administered intrarectally seven months after the booster.

This prime–boost strategy did not protect the animals from infection with SHIV but it did protect them from...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT